SCHEMBL2179191

SCHEMBL2179191

CNCCNCc1nnc2c(n1)c(=O)n(C)c(=O)n2C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
KDM4E B2RXH2 5/20 0.38
LMNA P02545 3/20 0.38
HPGD P15428 3/20 0.38
JAK2 O60674 1/20 0.38
HTT P42858 1/20 0.38
PAX8 Q06710 1/20 0.38
CASP1 P29466 3/20 0.38
CASP7 P55210 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP2C19 P33261 1/20 0.38
ADORA2A P29274 1/20 0.36
MAPT P10636 3/20 0.36
BLM P54132 2/20 0.33
POLB P06746 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 2/20 0.33
THRB P10828 1/20 0.33
MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178990 0.93 ALDH1A1 (0.38) ALDH1A1KDM4ELMNAHPGDJAK2
SCHEMBL2179999 0.87 LMNA (0.38) ALDH1A1KDM4ELMNAHPGDJAK2
SCHEMBL2182462 0.86 ALDH1A1 (0.38) ALDH1A1KDM4ELMNAHPGDJAK2
SCHEMBL2182956 0.85 CYP2C19 (0.40) ALDH1A1KDM4ELMNAHPGDJAK2
SCHEMBL2181663 0.84 CYP2D6 (0.48) ALDH1A1KDM4ELMNAHPGDJAK2
SCHEMBL2184303 0.83 LMNA (0.37) ALDH1A1KDM4ELMNAHPGDJAK2
SCHEMBL2183984 0.83 CYP2D6 (0.44) ALDH1A1KDM4ELMNAHPGDJAK2
SCHEMBL2181108 0.82 ADORA2A (0.38) ALDH1A1LMNAJAK2HTTADORA2A
SCHEMBL2183519 0.82 TP53 (0.41) ALDH1A1KDM4ELMNAHPGDJAK2
SCHEMBL2182443 0.81 LMNA (0.43) ALDH1A1KDM4ELMNAHPGDJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-07 US disclosed
WO-2010014798-A2 PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TCF4, TCF7L2, CTNNB1 ALDH1A1 1526/4885KDM4E 2362/4885LMNA 1229/4885
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same DPYD, TYMP, DHFR ALDH1A1 245/4885KDM4E 4180/4885LMNA 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.